DBV Technologies Future Growth

Future criteria checks 2/6

DBV Technologies is forecast to grow earnings and revenue by 2.1% and 44% per annum respectively while EPS is expected to grow by 53.4% per annum.

Key information

2.1%

Earnings growth rate

53.4%

EPS growth rate

Biotechs earnings growth	35.1%
Revenue growth rate	44.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	01 Aug 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:DBV0 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	14	-123	-189	-130	2
12/31/2025	5	-131	-178	-125	2
12/31/2024	5	-131	-216	-122	3
6/30/2024	14	-88	-105	-103	N/A
3/31/2024	15	-80	-95	-94	N/A
12/31/2023	16	-73	-80	-80	N/A
9/30/2023	6	-101	-90	-90	N/A
6/30/2023	5	-101	-91	-90	N/A
3/31/2023	4	-100	-76	-75	N/A
12/31/2022	5	-96	-56	-56	N/A
9/30/2022	9	-71	-52	-51	N/A
6/30/2022	8	-77	-55	-53	N/A
3/31/2022	5	-85	-74	-74	N/A
12/31/2021	6	-98	-109	-108	N/A
9/30/2021	2	-124	-124	-123	N/A
6/30/2021	4	-131	-144	-142	N/A
3/31/2021	9	-148	-154	-152	N/A
12/31/2020	11	-160	-168	-166	N/A
9/30/2020	17	-161	-157	-153	N/A
6/30/2020	16	-171	-156	-151	N/A
3/31/2020	16	-169	-161	-156	N/A
12/31/2019	15	-172	-154	-148	N/A
9/30/2019	12	-176	-156	-151	N/A
6/30/2019	13	-198	-176	-169	N/A
3/31/2019	13	-191	-166	-160	N/A
12/31/2018	13	-190	-162	-157	N/A
9/30/2018	11	-178	-164	-157	N/A
6/30/2018	11	-172	-150	-145	N/A
3/31/2018	11	-182	N/A	-147	N/A
12/31/2017	12	-177	N/A	-137	N/A
9/30/2017	11	-169	N/A	-118	N/A
6/30/2017	11	-157	N/A	-97	N/A
3/31/2017	9	-135	N/A	-77	N/A
12/31/2016	8	-121	N/A	-63	N/A
9/30/2016	8	-109	N/A	-58	N/A
6/30/2016	8	-88	N/A	-49	N/A
3/31/2016	8	-72	N/A	-41	N/A
12/31/2015	7	-49	N/A	-29	N/A
9/30/2015	6	-40	N/A	-28	N/A
6/30/2015	6	-30	N/A	-25	N/A
3/31/2015	5	-27	N/A	-23	N/A
12/31/2014	6	-29	N/A	-25	N/A
9/30/2014	6	-30	N/A	-24	N/A
6/30/2014	7	-32	N/A	-25	N/A
3/31/2014	6	-28	N/A	-21	N/A
12/31/2013	5	-27	N/A	-18	N/A
9/30/2013	4	-23	N/A	-16	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DBV0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DBV0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DBV0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DBV0's revenue (44% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: DBV0's revenue (44% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if DBV0's Return on Equity is forecast to be high in 3 years time

DBV Technologies Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

DBV Technologies S.A. to Report Q2, 2024 Results on Jul 30, 2024

DBV Technologies Provides Non-Compliance Update Related to Nasdaq Listing Rule 5550(a)(2) & 5810(c)(3)(A)

DBV Technologies S.A., Annual General Meeting, May 16, 2024

DBV Technologies S.A. to Report Fiscal Year 2023 Results on Mar 07, 2024

DBV Technologies Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

DBV Technologies S.A. to Present New Data at ACAAI 2023

DBV Technologies S.A. to Report Q3, 2023 Results on Oct 31, 2023

DBV Technologies S.A. Announces Executive Changes

DBV Technologies S.A. Announces Executive Changes

Dbv Technologies S.A. Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies

DBV Technologies S.A. to Report First Half, 2023 Results on Jul 31, 2023

DBV Technologies Announces FDA Lifts Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial

DBV Technologies S.A. Announces Executive Changes

DBV Technologies S.A. Receives Feedback from the U.S. Food and Drug Administration in the Form of a Partial Clinical Hold on Its VITESSE Phase 3 Clinical Study

DBV Technologies S.A. Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

DBV Technologies S.A. announced that it has received €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, Fairmount Funds Management LLC

DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor

DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor

DBV Technologies Announces Positive Topline Results from Phase 3 Epitope Trial of Viaskin Peanut in Peanut-Allergic Toddlers

DBV Technologies S.A. to Report Q1, 2022 Results on May 02, 2022

DBV Technologies S.A. Provides Update on Investigational Viaskin Peanut

DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer

DBV Technologies S.A. to Report First Half, 2021 Results on Aug 02, 2021

DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years

Hugh Sampson Decides to Step Down as Chief Scientific Officer of DBV Technologies, Effective December 1, 2020

DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020

DBV Technologies S.A. Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies